Amgen Archives -

Amgen eyes swift move to ph3 for cardiovascular drug olpasiran

Phil Taylor Amgen, atherosclerosis, gene silencing, lipoprotein(a), Novartis, olpasiran, pelacarsen, Silence Therapeutics, siRNA, SLN360 0 Comment

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible

Amgen eyes swift move to ph3 for cardiovascular drug olpasiran

https://pharmaphorum.com/news/amgen-eyes-swift-move-to-ph3-for-cardiovascular-drug-olpasiran/

News/ News/ Oncology

Mirati heads for FDA verdict on KRAS drug with new data

Phil Taylor adagrasib, Amgen, asco, KRAS, Lumakras, Mirati, Non-small cell lung cancer 0 Comment

Mirati Therapeutics will hear from the FDA on its KRAS inhibitor adagrasib later this year, hoping to compete

Mirati heads for FDA verdict on KRAS drug with new data

https://pharmaphorum.com/news/mirati-heads-for-fda-verdict-on-kras-drug-with-new-data/

News/ News/ Oncology

AACR: Novartis joins the KRAS clan, eyeing swift move to phase 3

Phil Taylor Amgen, KRAS, Lumakras, Mirati, Non-small cell lung cancer, Novartis, novel targeted cancer treatments, Oncology 0 Comment

Novartis has joined the select cadre of drugmakers developing KRAS inhibitors for cancer, opening its account with phase

AACR: Novartis joins the KRAS clan, eyeing swift move to phase 3

https://pharmaphorum.com/news/aacr-novartis-joins-the-kras-clan-eyeing-swift-move-to-phase-3/

Market Access/ News/ News

NICE ends UK access disparity to osteoporosis drug Evenity

Phil Taylor Amgen, Evenity, HEOR, NHS, osteoporosis, UCB 0 Comment

NICE has reversed its stance on UCB and Amgen’s severe osteoporosis therapy Evenity, saying out can be prescribed

NICE ends UK access disparity to osteoporosis drug Evenity

https://pharmaphorum.com/news/nice-ends-uk-access-disparity-to-osteoporosis-drug-evenity/

News/ News/ Oncology

Amgen eyes pancreatic cancer use for its pathfinder KRAS drug

Phil Taylor Amgen, KRAS, Lumakras, Mirati, pancreatic cancer 0 Comment

Armed with new clinical trial results, Amgen is expanding studies of its KRAS inhibitor Lumakras in pancreatic cancer,

Amgen eyes pancreatic cancer use for its pathfinder KRAS drug

https://pharmaphorum.com/news/amgen-eyes-pancreatic-cancer-use-for-kras-drug/

News/ News/ Oncology

Amgen grabs EU approval for pathfinder KRAS drug Lumykras

Phil Taylor Amgen, KRAS, Lumakras, Lumykras, Non-small cell lung cancer, Oncology, targeted oncology 0 Comment

Amgen now has regulatory approval on both sides of the Atlantic for Lumykras, the culmination of many years

Amgen grabs EU approval for pathfinder KRAS drug Lumykras

https://pharmaphorum.com/news/amgen-grabs-eu-approval-for-pathfinder-kras-drug-lumykras/

News/ News/ R&D

Amgen pledges $1.9bn to alliance with AI specialist Generate

Phil Taylor Amgen, artificial intelligence, drug discovery, Generate Biomedicines, protein 0 Comment

Fresh from a sizeable funding round that raised $370 million, artificial intelligence-based drug discovery firm Generate Biomedicines has

Amgen pledges $1.9bn to alliance with AI specialist Generate

https://pharmaphorum.com/news/amgen-pledges-1-9bn-to-alliance-with-ai-specialist-generate/

News/ News/ Sales and Marketing

Novartis bags elusive US approval for cholesterol drug inclisiran

Phil Taylor Amgen, cholesterol, inclisiran, Leqvio, Novartis, PCSK9, Praluent, Regeneron, regulatory approval, Repatha, Sanofi 0 Comment

At its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce

Novartis bags elusive US approval for cholesterol drug inclisiran

https://pharmaphorum.com/news/novartis-bags-elusive-us-approval-for-cholesterol-drug-inclisiran/

News/ News/ Sales and Marketing

Amgen builds Otezla’s psoriasis label as rival BMS looms large

Phil Taylor Amgen, Bristol-Myers Squibb, deucravacitinib, Otezla, psoriasis, sales & marketing 0 Comment

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it

Amgen builds Otezla’s psoriasis label as rival BMS looms large

https://pharmaphorum.com/news/amgen-builds-otezlas-psoriasis-label-as-rival-bms-looms-large/

Trending

Amgen

Login